Study guide

12.1 Stone Pathophysiology & Risk Factors

FEBU Part 1 Written European Board of Urology

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice

2 Chapter 2: Genitourinary Anatomy & Renal Physiology

2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance

3 Chapter 3: Urological Pharmacology & Diagnostic Imaging

3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine

4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification

4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging

5 Chapter 5: Prostate Cancer: Localized & Advanced Management

5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)

6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)

6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy

7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma

7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)

8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms

8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas

9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer

9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy

10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms

10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO

11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology

11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation

12 Chapter 12: Urolithiasis: Evaluation & Medical Management

12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy

13 Chapter 13: Endourology & Interventional Stone Management

13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety

14 Chapter 14: Infections, Andrology & Male Infertility

14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery

15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation

15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation

12.1 Stone Pathophysiology & Risk Factors

Key Takeaways Explain This Topic AI

Urinary stone formation is driven by physicochemical transitions: supersaturation, crystal nucleation (homogeneous vs heterogeneous), crystal growth, and aggregation into clinically detectable calculi.

Randall's plaques originate as calcium phosphate (apatite) deposits in the basement membrane of the thin loops of Henle that erode into the papillary urothelium to act as a nidus for calcium oxalate stones, whereas Randall's plugs represent crystal deposits within the collecting ducts of Bellini.

Stone compositions exhibit distinct crystallographic and radiological features: calcium oxalate monohydrate (whewellite; dense, radio-opaque, hard, 1100–1500 HU), calcium oxalate dihydrate (weddellite; envelope-shaped, SWL-susceptible, 800–1200 HU), brushite (SWL-resistant, 1200–1800 HU, pH > 6.5), uric acid (radiolucent on KUB, 300–500 HU, pH < 5.5), and struvite (coffin-lid, urease-induced, pH > 7.2).

Cystinuria is caused by an autosomal recessive defect in the SLC3A1 or SLC7A9 dibasic amino acid transporter (COLA: cystine, ornithine, lysine, arginine), forming pathognomonic hexagonal crystals with ground-glass radio-opacity (600–900 HU).

Indinavir stones are classically radiolucent on both plain radiography and standard non-contrast CT. A negative NCCT therefore does not exclude this drug-related cause of obstruction.

Last updated: November 2026

Stone Pathophysiology & Risk Factors

Urolithiasis is a complex multifactorial disease that arises from physicochemical imbalances in urinary solute concentrations and tubular epithelial interactions. Understanding the crystallization cascade—from ionic thermodynamic saturation to anchored papillary calculus growth—is essential for interpreting diagnostic imaging, selecting interventional lithotripsy modalities, and formulating targeted recurrence prevention strategies under European Board of Urology (EBU) and European Association of Urology (EAU) frameworks.

Physicochemical Principles of Calculus Formation

Urinary calculus formation is fundamentally a phase change process wherein dissolved urinary solutes precipitate into solid crystalline lattices. This phenomenon is governed by thermodynamic supersaturation, kinetic nucleation thresholds, crystal growth kinetics, and particle aggregation.

Supersaturation and Saturation Zones

The driving thermodynamic force for crystallization is urinary supersaturation , quantitatively expressed as the Relative Supersaturation (RSS) . RSS represents the ratio of the chemical activity product of stone-forming ions in urine to their thermodynamic solubility product ( K s p K_{sp} K s p ​ ) in pure aqueous solution at 37°C:

Undersaturated Zone ( R S S < 1.0 RSS < 1.0 RSS < 1.0 ) : The concentration of solute ions is below the thermodynamic solubility limit. Existing crystals placed in this urine will spontaneously dissolve. Calculus formation is thermodynamically impossible.

Metastable Zone (above saturation but below the formation threshold) : The solute concentration exceeds the solubility product ( K s p K_{sp} K s p ​ ) but remains below the formation product ( F P FP FP ) (also termed the upper limit of metastability). In this state, the free energy barrier prevents spontaneous de novo crystal precipitation. However, if a pre-existing crystal seed, cell debris, or foreign surface is introduced, heterogeneous crystal growth and aggregation can proceed readily.

Labile (Unstable) Zone (above the formation threshold) : Solute concentration exceeds the formation product. The free energy barrier is overcome, triggering rapid, spontaneous homogeneous nucleation without requiring pre-existing surfaces.

Crystal Nucleation: Homogeneous vs. Heterogeneous

Nucleation represents the initial clustering of dissolved ionic species into a stable microscopic solid-phase nucleus capable of sustained growth:

Homogeneous Nucleation : Occurs in pure solution free of foreign surfaces or impurities. Because it requires extremely high activation energy, homogeneous nucleation occurs clinically only at extreme levels of supersaturation deep within the labile zone.

Heterogeneous Nucleation : Occurs when crystals precipitate onto pre-existing surfaces, such as cell debris, cast matrices, lipid membranes, or pre-existing crystals of a different composition. Heterogeneous nucleation drastically lowers the interfacial energy and activation energy barrier, enabling rapid stone formation at modest supersaturation levels within the metastable zone.

Epitaxy : A specialized subtype of heterogeneous nucleation where crystals of one substance (e.g., calcium oxalate) nucleate and grow directly upon the crystalline lattice of a distinct mineral substrate (e.g., apatite or uric acid) due to precise geometrical and structural matching of their crystal lattice spacing.

Crystal Growth, Aggregation, and Inhibitor Dynamics

Following nucleation, crystal mass expands through two distinct mechanisms:

Crystal Growth : The ordered addition of individual ionic solute units from the surrounding supersaturated liquid onto the active growth sites of the crystal lattice.

Crystal Aggregation : The agglomeration and fusing of multiple pre-formed microcrystals into macroscopic multicrystalline clusters. Aggregation is kinetically much faster than crystal growth alone and represents the primary mechanism responsible for producing particles large enough to lodge within collecting duct lumina.

Under physiological conditions, healthy human urine contains potent macromolecular and micromolecular inhibitors that suppress nucleation, crystal growth, and aggregation:

Micromolecular Inhibitors : Citrate (the most potent natural inhibitor, which complexes ionized calcium into soluble calcium-citrate chelates, reducing free ionized calcium activity while directly poisoning calcium phosphate crystal growth sites), magnesium (competes with calcium for oxalate binding, forming soluble magnesium oxalate complexes), and pyrophosphate .

Macromolecular Inhibitors : Glycoproteins such as uromodulin (Tamm-Horsfall protein) , osteopontin , nephrocalcin , and urinary prothrombin fragment 1 (UPTF-1) . These polyanionic macromolecules adsorb onto crystal surfaces, imparting a negative surface charge (zeta potential) that electrostatically repels adjacent crystals and halts aggregation.

Papillary Anatomy and Calculus Anchoring: Randall's Plaques vs. Randall's Plugs

For a crystalline particle to develop into a clinically significant calculus, it must be retained within the renal collecting system rather than being swept out by physiological urinary flow (the so-called free-particle versus fixed-particle mechanisms). Alexander Randall identified distinct anatomical anchoring mechanisms that explain different pathways of stone pathogenesis. +------------------------------------------------------------------------------------------------+

  • | RANDALL'S PLAQUE PATHWAY |
  • | |
  • | Hypercalciuria / Medullary Gradient |
  • | --> Apatite precipitation in basement membrane of thin loops of Henle |
  • | --> Spreads through medullary interstitium to renal papillary tip |
  • | --> Erodes through overlying papillary urothelium into urinary space |
  • | --> Adsorption of urinary proteins creates organic protein matrix |
  • | --> Heterogeneous nucleation & epitaxial overgrowth of Calcium Oxalate Monohydrate (COM) |
  • +------------------------------------------------------------------------------------------------+

vs.

  • +------------------------------------------------------------------------------------------------+
  • | RANDALL'S PLUG PATHWAY |
  • | |
  • | Severe Tubular Supersaturation (e.g., Brushite, Cystinuria, Enteric Hyperoxaluria) |
  • | --> Intraluminal crystal precipitation inside terminal Ducts of Bellini |
  • | --> Obstruction of duct lumen with mechanical plugging and tubular cell necrosis |
  • | --> Protrusion of crystalline plug into calyx, acting as nidus for secondary calculus growth |
  • +------------------------------------------------------------------------------------------------+
  • Randall's Plaques

Histological Origin : Initiates as tiny spherules of calcium phosphate (carbonated apatite) in the basement membrane of the thin descending and ascending limbs of Henle's loop in the deep inner medulla.

Pathogenesis : High interstitial calcium and phosphate concentrations within the countercurrent medullary gradient cause interstitial apatite mineralization. Over years, these mineral deposits coalesce and spread through the medullary interstitium toward the apex of the renal papilla.

Urothelial Erosion and Overgrowth : As interstitial plaques reach the papillary surface, the overlying urothelium undergoes localized degeneration and sloughs away. The exposed apatite plaque is directly bathed in supersaturated pelvic urine, rapidly acquiring an organic macromolecular coat (osteopontin and Tamm-Horsfall protein). This coated apatite surface serves as the ideal nidus for the epitaxial, heterogeneous overgrowth of calcium oxalate monohydrate (COM) stones.

Clinical Associations : Found in almost 100% of idiopathic calcium oxalate stone formers . The total papillary surface area covered by Randall's plaques correlates directly with 24-hour urinary calcium excretion and clinical stone recurrence rates.

Randall's Plugs (Ductal Plugs)

Histological Origin : Intratubular, intraluminal crystalline plugs located within the terminal ducts of Bellini .

Pathogenesis : Severe intraluminal supersaturation leads to massive crystal precipitation within the tubule itself. The growing crystalline aggregate obstructs the collecting duct lumen, inducing mechanical compression, epithelial denudation, tubular cell necrosis, and adjacent interstitial fibrosis.

Crystalline Composition : Typically composed of brushite (calcium hydrogen phosphate dihydrate) , carbonate apatite , or cystine .

Clinical Associations : Characteristically observed in aggressive, destructive stone-forming conditions, including brushite stone disease , primary hyperparathyroidism , distal renal tubular acidosis (Type 1 dRTA) , enteric hyperoxaluria following bariatric surgery or ileal resection, and severe cystinuria .

Stone Compositions and Radiological Characteristics

Understanding the physical, crystallographic, and radiological properties of specific stone types guides both diagnostic interpretation (e.g., non-contrast CT Hounsfield units and plain radiography) and surgical treatment selection.

1. Calcium Oxalate Monohydrate (COM / Whewellite, C a C 2 O 4 ⋅ H 2 O CaC_2O_4 \cdot H_2O C a C 2 ​ O 4 ​ ⋅ H 2 ​ O )

Crystal Morphology : Biconcave ovals, dumbbells, or rounded spheres on light microscopy; exhibits strong birefringence under polarized light.

Physical Properties : Extremely hard, dense, and compact stone matrix. Frequently presents with a dark brown or black smooth surface ("hempseed" appearance) or a tuberculated "mulberry" exterior.

Radiological Features : Dense, sharp radio-opacity on plain KUB radiographs; high attenuation on non-contrast CT ( 1100–1500 HU ).

Surgical Implication : Due to its dense, non-porous microcrystalline structure, COM is relatively resistant to shock wave lithotripsy (SWL), requiring higher shock numbers and energy levels or endourological extraction (URS / PCNL).

Urine pH : Crystallizes independently of urinary pH across the physiological range (pH 5.0–7.5).

2. Calcium Oxalate Dihydrate (COD / Weddellite, C a C 2 O 4 ⋅ 2 H 2 O CaC_2O_4 \cdot 2H_2O C a C 2 ​ O 4 ​ ⋅ 2 H 2 ​ O )

Crystal Morphology : Pathognomonic bipyramidal, envelope-shaped crystals ("letter envelopes").

Physical Properties : Light yellow to pale brown, porous, spicular, and jagged surface.

Radiological Features : Radio-opaque on KUB; non-contrast CT attenuation typically 800–1200 HU .

Surgical Implication : Highly fragile and brittle with poor internal cohesive strength; exhibits excellent fragmentation susceptibility under SWL .

Etiology : Strongly associated with acute surges in urinary calcium concentration (severe hypercalciuria). Over time, COD can undergo spontaneous phase transition and convert to thermodynamically stable COM.

3. Calcium Phosphate Stones: Apatite vs. Brushite

Calcium phosphate stones are divided into two distinct clinical and crystallographic entities:

Carbonate Apatite / Dahllite ( C a 10 ( P O 4 , C O 3 ) 6 ( O H ) 2 Ca_{10}(PO_4,CO_3)_6(OH)_2 C a 10 ​ ( P O 4 ​ , C O 3 ​ ) 6 ​ ( O H ) 2 ​ ) :

Crystal morphology: Amorphous, fine microcrystalline granular aggregates.

Radiography: Moderately to highly radio-opaque on KUB; CT attenuation 1000–1400 HU .

Urine pH: Crystallization is favored in alkaline urine, typically pH >6.8 .

Associations: Frequently co-precipitates with struvite in infection stones or arises in distal renal tubular acidosis (dRTA) and primary hyperparathyroidism.

Brushite (Calcium Hydrogen Phosphate Dihydrate, C a H P O 4 ⋅ 2 H 2 O CaHPO_4 \cdot 2H_2O C a H P O 4 ​ ⋅ 2 H 2 ​ O ) :

Crystal morphology: Elongated, monoclinic prisms, needle-shaped crystals, or radiating star-like clusters.

Radiography: Highly radio-opaque on KUB; CT attenuation 1200–1800 HU (high attenuation, with overlap between stone types).

Physical Properties: Unusually hard, solid, and non-cleavable.

Surgical Implication: Extremely resistant to shock wave lithotripsy (SWL) . Brushite predicts poor SWL fragmentation. Flexible ureterorenoscopy (fURS) or PCNL is often preferable when intervention is needed; select treatment by size, location, anatomy and patient factors.

Clinical Course: Aggressive recurrence rates with rapid formation of ductal Bellini plugs and secondary nephron loss.

4. Uric Acid Stones ( C 5 H 4 N 4 O 3 C_5H_4N_4O_3 C 5 ​ H 4 ​ N 4 ​ O 3 ​ )

Crystal Morphology : Pleomorphic, diamond-shaped, rhomboid, barrel-shaped, or rosette crystals; highly birefringent under polarized light.

Physical Properties : Soft, orange-to-yellow or red-brown stones (stained by urinary pigment coproporphyrin).

Radiological Features :

Plain KUB : Completely radiolucent (invisible on plain film) due to low effective atomic number ( Z e f f Z_{eff} Z e ff ​ ). Can occasionally appear faintly visible if mixed with trace calcium phosphate.

Non-Contrast CT (NCCT) : Readily visible with low attenuation values ( 300–500 HU ).

Dual-Energy CT (DECT) : DECT easily discriminates uric acid from calcium-containing calculi based on the low ratio of low-energy to high-energy X-ray attenuation.

Pathophysiology : Driven primarily by excessively acidic urinary pH (< 5.5) rather than absolute hyperuricosuria. The dissociation constant ( p K a pK_a p K a ​ ) of uric acid is 5.35 . At a urine pH of 5.35, exactly 50% of uric acid exists in the poorly soluble undissociated form (solubility limit ~100 mg/L). The undissociated fraction is 1 / ( 1 + 10 p H − 5.35 ) 1/(1+10^{pH-5.35}) 1/ ( 1 + 1 0 p H − 5.35 ) : approximately 69% at pH 5.0 and 74% at pH 4.9. Lower pH reduces solubility and favors crystallization.

Etiology : Metabolic syndrome (insulin resistance impairs renal ammoniagenesis, leading to unbuffered acidic urine), chronic diarrheal states (gastrointestinal bicarbonate loss), high purine diet, and myeloproliferative disorders.

5. Magnesium Ammonium Phosphate (Struvite, M g N H 4 P O 4 ⋅ 6 H 2 O MgNH_4PO_4 \cdot 6H_2O M g N H 4 ​ P O 4 ​ ⋅ 6 H 2 ​ O ) & Carbonate Apatite

Crystal Morphology : Characteristic rectangular, three-dimensional "coffin-lid" prismatic crystals.

Physical Properties : Soft, chalky, pale-yellow or dirty-white calculi that rapidly expand into massive branched staghorn calculi filling the renal pelvis and calyces.

Radiological Features : Variable radio-opacity on KUB (moderately radio-opaque, often with laminated ground-glass architecture); CT attenuation 600–900 HU .

Microbiology and Mechanism : Infection stones occur exclusively in the presence of urease-producing microorganisms :

Common pathogens: Proteus mirabilis (most frequent, ~70%), Klebsiella pneumoniae , Pseudomonas aeruginosa , Providencia , Morganella morganii , Serratia marcescens , Staphylococcus saprophyticus , and Ureaplasma urealyticum .

Important

Escherichia coli does NOT produce urease . A struvite stone cannot be caused by E. coli alone; when isolated in urine cultures alongside struvite stones, E. coli represents a secondary superinfection or bystander.

Biochemical reaction: Bacterial urease enzymatically hydrolyzes urea into ammonia and carbon dioxide: C O ( N H 2 ) 2 + H 2 O → urease 2 N H 3 + C O 2 CO(NH_2)_2 + H_2O \xrightarrow{\text{urease}} 2NH_3 + CO_2 CO ( N H 2 ​ ) 2 ​ + H 2 ​ O urease ​ 2 N H 3 ​ + C O 2 ​ Ammonia binds water to produce ammonium ( N H 4 + NH_4^+ N H 4 + ​ ) and free hydroxyl ( O H − OH^- O H − ) ions, driving urinary pH into markedly alkaline ranges ( pH > 7.2 , frequently > 8.0 > 8.0 > 8.0 ). This alkaline environment shifts bicarbonate toward carbonate, favoring precipitation of magnesium ammonium phosphate (struvite) and carbonate apatite.

6. Cystine Stones

Crystal Morphology : Pathognomonic, flat, colorless, perfectly symmetrical hexagonal plates ("benzene rings"); weakly birefringent under polarized light.

Radiological Features : Faintly radio-opaque on plain KUB with a smooth, waxy, "ground-glass" appearance (owing to the high atomic number of constituent sulfur atoms); CT attenuation 600–900 HU .

Pathophysiology : Autosomal recessive inborn error of metabolism affecting the heteromeric amino acid transporter in the apical brush border of proximal renal tubular and jejunal enterocytes:

Type A Cystinuria : Mutations in the SLC3A1 gene on chromosome 2p (encodes the rBAT heavy subunit).

Type B Cystinuria : Mutations in the SLC7A9 gene on chromosome 19q (encodes the b 0 , + A T b^{0,+}AT b 0 , + A T light subunit).

The defective transporter fails to reabsorb dibasic amino acids, summarized by the acronym COLA :

  • C ystine
  • O rnithine
  • L ysine
  • A rginine

While ornithine, lysine, and arginine are highly soluble, cystine (two cysteine molecules linked by a disulfide bridge) is exceptionally insoluble at physiological urine pH. Its solubility threshold is approximately 250 mg/L (1.0 mmol/L) between pH 5.0 and 7.0.

Screening Test : Qualitative sodium cyanide-nitroprusside test (Brand's test): cyanide reduces cystine to cysteine; free sulfhydryl groups react with nitroprusside to produce an intense magenta / cherry-red color (positive if urinary cystine exceeds 75 mg/L).

7. Drug-Induced Calculi

Indinavir Calculi : A protease inhibitor used in antiretroviral therapy. Precipitates into fan-shaped or needle-like crystal rosettes. Classically not visible on plain KUB or non-contrast CT . If obstruction remains suspected despite a negative NCCT, assess secondary signs and arrange further urological imaging as appropriate rather than excluding a stone.

Triamterene : Potassium-sparing diuretic; yields greenish-brown, faint radio-opaque stones with characteristic golden-brown fluorescent needle crystals.

Atazanavir, Sulfadiazine (shocks of wheat crystals), Ciprofloxacin .

Comprehensive Stone Composition Comparison

Stone Variety Mineral Name & Formula Crystal Microscopy Plain KUB Appearance CT Density (Hounsfield Units) Urine pH Dependency Predisposing Etiologies & Risk Factors

Calcium Oxalate Monohydrate Whewellite ( C a C 2 O 4 ⋅ H 2 O CaC_2O_4 \cdot H_2O C a C 2 ​ O 4 ​ ⋅ H 2 ​ O ) Biconcave ovals, dumbbells, spheres Dense, sharp radio-opaque 1100–1500 HU Independent (pH 5.0–7.5) Idiopathic hypercalciuria, hyperoxaluria, low fluid intake, hypocitraturia

Calcium Oxalate Dihydrate Weddellite ( C a C 2 O 4 ⋅ 2 H 2 O CaC_2O_4 \cdot 2H_2O C a C 2 ​ O 4 ​ ⋅ 2 H 2 ​ O ) Bipyramidal, envelope-shaped Moderately radio-opaque 800–1200 HU Independent (pH 5.0–7.5) Hypercalciuria; generally more susceptible to SWL than COM

Brushite Calcium Hydrogen Phosphate Dihydrate ( C a H P O 4 ⋅ 2 H 2 O CaHPO_4 \cdot 2H_2O C a H P O 4 ​ ⋅ 2 H 2 ​ O ) Monoclinic needles, radiating prisms Dense radio-opaque 1200–1800 HU Alkaline (pH 6.5–6.8) Primary hyperparathyroidism, dRTA; highly resistant to SWL comminution

Carbonate Apatite Dahllite ( C a 10 ( P O 4 , C O 3 ) 6 ( O H ) 2 Ca_{10}(PO_4,CO_3)_6(OH)_2 C a 10 ​ ( P O 4 ​ , C O 3 ​ ) 6 ​ ( O H ) 2 ​ ) Amorphous, granular aggregates Moderately radio-opaque 1000–1400 HU Alkaline (pH >6.8) Distal RTA (Type 1), hyperparathyroidism, urease urinary tract infections

Uric Acid Anhydrous Uric Acid ( C 5 H 4 N 4 O 3 C_5H_4N_4O_3 C 5 ​ H 4 ​ N 4 ​ O 3 ​ ) Rhomboids, diamonds, rosettes Radiolucent (invisible) 300–500 HU Acidic (pH < 5.5) Low urine pH, metabolic syndrome, gout, purine gluttony, dehydration

Struvite (Infection) Magnesium Ammonium Phosphate ( M g N H 4 P O 4 ⋅ 6 H 2 O MgNH_4PO_4 \cdot 6H_2O M g N H 4 ​ P O 4 ​ ⋅ 6 H 2 ​ O ) Rectangular "coffin-lid" prisms Ground-glass / laminated opaque 600–900 HU Strongly alkaline (pH > 7.2) Urease-producing bacteria ( Proteus , Klebsiella , Pseudomonas ); staghorn calculi

Cystine L-Cystine ( C 6 H 12 N 2 O 4 S 2 C_6H_{12}N_2O_4S_2 C 6 ​ H 12 ​ N 2 ​ O 4 ​ S 2 ​ ) Hexagonal, benzene-like plates Faint "ground-glass" opacity 600–900 HU Acidic / Neutral (pH < 7.0) Inborn defect in dibasic amino acid transporter ( SLC3A1 , SLC7A9 )

Indinavir Indinavir Sulfate Rosettes of fine needles Completely radiolucent Often not visualized on NCCT Alkaline / Neutral Antiretroviral HIV protease inhibitor therapy; invisible on non-contrast CT